PTC Therapeutics Inc

24 Aug 2026, 19:56 UTC

PTC Therapeutics shares rise as new data shows Sephience treatment significantly reduces blood phenylalanine levels in patients with phenylketonuria.

21 Aug 2026, 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

20 Aug 2026, 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

19 Aug 2026, 19:46 UTC

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

18 Aug 2026, 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

14 Aug 2026, 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13 Aug 2026, 19:36 UTC

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12 Aug 2026, 23:51 UTC

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11 Aug 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10 Aug 2026, 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7 Aug 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6 Aug 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5 Aug 2026, 19:26 UTC

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4 Aug 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3 Aug 2026, 19:46 UTC

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31 Jul 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30 Jul 2026, 22:31 UTC

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29 Jul 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28 Jul 2026, 18:31 UTC

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27 Jul 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22 Jul 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21 Jul 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20 Jul 2026, 19:56 UTC

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.